Health Populi

MAY 14, 2018

This is what happened to pharma stock prices on Friday after President Trump and Secretary of Health and Human Services Alex Azar outlined their new policies focusing on prescription drug prices. Seniors and government programs over-paying for drugs. The graph is the Nasdaq U.S.

Prescription Drug Pricing 48

Prescription Drug Pricing Governance ACA Medicare 48

Health Populi

OCTOBER 12, 2018

Since the CVS+Aetna announcement last December, the Kaiser Family Foundation ran some numbers on how the merged organization could impact Medicare — a key payor for both health insurance and prescription drugs under Part D. The Academy convened a team with experience and gravitas to inform this report.

US Department of Health and Human Services 58

US Department of Health and Human Services Prescription Drug Pricing Health Insurance Medicare 58

Health Populi

MARCH 13, 2018

Health Populi’s Hot Points: The big wild card in forecasting what prescription drug spending will look like in the U.S. is just how aggressive Dr. Alex Azar at the Department of Health and Human Services, and Dr. Scott Gottlieb at FDA, want to be regarding drug pricing.

Prescription Drug Pricing 67

Prescription Drug Pricing FDA Hospitals Medicare 67

Health Populi

AUGUST 3, 2018

A new poll jointly conducted by Politico and the Harvard Chan School of Public Health bolsters my read on the latter issue – prescription drug pricing, which has become a mass popular culture union. This is the tactic that most Americans say could lower prescription drug prices. Why should U.S.

Prescription Drug Pricing 67

Prescription Drug Pricing FDA Public Health Medicare 67

Health Populi

FEBRUARY 4, 2020

voters’ priorities, across political party – prescription drug prices. voters in 2020 quite like supporting Medicare’s ability to negotiate drug prices with pharmaceutical companies, shown by the October 2019 Kaiser Family Foundation Health Tracking Poll. Few issues unite U.S.

Prescription Drug Pricing 77

Prescription Drug Pricing Medicare Medicare Health Insurance 77

Drug & Device Law

OCTOBER 10, 2022

The manufacturer sought to cover Medicare patients’ Part D cost-sharing obligations for the drug – which were estimated at approximately $13,000 per year – but the OIG said “no thanks,” and the Second Circuit has affirmed that outcome. That being said, Medicare does not cover the entire cost of the drug. 1320a-7b (“AKS”).

Medicare 52

Medicare Medicare FDA Prescription Drug Pricing 52